
    study stopped due to low enrollment
  
['chronic hepatitis c infection']
['ombitasvir/paritaprevir/ritonavir and dasabuvir', 'ombitasvir/paritaprevir/ritonavir', 'ribavirin']

        Inclusion Criteria:

          1. Male or female, at least 18 years of age at time of screening

          2. Chronic hepatitis C virus (HCV) infection prior to study enrollment with screening
             laboratory results indicating HCV genotype 1 or 4 infection

          3. Early stage hepatocellular carcinoma (HCC) diagnosed based on the typical hallmark of
             HCC (hypervascular in the arterial phase with washout in the portal venous or delayed
             phases)

          4. Compensated cirrhosis defined as a Child-Pugh score of 5 or 6 at Screening

             • A minimal rim of ascites if detected at imaging is acceptable. Exclude ascites that
             requires the need to apply diuretic treatment to control ascites

          5. Documented complete response to HCC treatment.

          6. Females must be post-menopausal for more than 2 years or surgically sterile or
             practicing acceptable forms of birth control.

        Exclusion Criteria:

          1. Use of known strong or moderate inducers of cytochrome P450 3A (CYP3A) in participants
             receiving ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) with and without dasabuvir
             (DSV), strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450 2C8
             (CYP2C8) in participants receiving OBV/PTV/r with DSV, medications contraindicated for
             ritonavir or RBV (for those that receive RBV) within 2 weeks or 10 half-lives (if
             known), whichever is longer, prior to study drug . For medications contraindicated
             with AbbVie's 2-direct-acting antiviral agent (2-DAA) and 3-DAA regimen, refer to the
             recommended prescribing information section of the approved local product labels.

          2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus antibody (HIV Ab).

          3. Patients regardless of eligibility to liver transplant, who have a comorbid disease
             that might preclude completion of study follow-up.

          4. Clinically significant abnormalities, other than HCV infection, in a participant with
             HCC based upon the medical history, physical examination, vital signs, laboratory
             profile and a 12-lead electrocardiogram (ECG) that make the participant an unsuitable
             candidate for this study in the opinion of the investigator.
      